Novo bets big on diabetes meds

Share this article:

Novo Nordisk is investing $3.65 billion in needle-free diabetes treatments. Reuters reports that the drug maker is looking to develop pills that can replace injected insulins, and tells the news service it has dedicated 500 employees to developing six candidates.

The company projects that it could have the new medication market-ready in 10 years.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.